Targeting CD44 and the Hippo-YAP pathway might be a potential treatment for docetaxel-resistant prostate adenocarcinoma, as docetaxel is a common drug used for metastatic prostatic carcinoma, migration, and invasion of docetaxel-resistant prostate carcinoma cells is promoted by CD44 via induction of Hippo-Yap signaling [20]. This evidence concerns the gene CD44 and prostate adenocarcinoma.